AdventHealth’s Karen D. Corbin, PhD, RD, Contributed to New American Diabetes Association Consensus Statement on Liver Disease in Diabetes

Published date: |
Estimated read time: |
Authored by:
  • AdventHealth
Topics:
Care Community Perspectives

“This new consensus statement is of critical importance as the number of people with metabolic dysfunction associated steatotic liver disease (MASLD) is on the rise. Many health care professionals have limited knowledge on how to best help people with diabetes who are at risk of liver disease, and our panel wanted to help bridge this knowledge gap.” -- Karen D. Corbin, PhD, RD, AdventHealth Translational Research Institute (TRI)

MASLD, formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at increased risk for metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality.

AdventHealth TRI’s Dr. Karen Corbin served on a panel of leading experts from across the country who developed and recently released the first American Diabetes Association (ADA) consensus statement on liver disease in people with type 2 diabetes. It emphasized the need for screening and early intervention to slow disease progression and improve outcomes.

Read the full article here.

Recent News

View More Articles